Genetech is proposing what they’re terming a “Combination Pricing Pilot” plan for its Avastin and Tecentriq offerings when the drugs are used together to treat lung cancer patients. The proposed policy, now under consideration by the US FDA, HHS, and the Centers for Medicare and Medicaid Services, would lower the prices for each drug, when used in combination. Dive more deeply into the plan and understand how its proposal ties into Genetech’s interest in Medicare Part B pricing reform, with incisive reporting from Pink Sheet.